What does the FDA approval of Vera’s Trutakna mean for IgA nephropathy treatment?

The FDA has approved Vera Therapeutics’ Trutakna for treating IgA nephropathy, marking the company’s first commercial product. The decision positions Vera within a competitive kidney‑disease market and shifts its focus from clinical development to commercialization, with investor attention now on launch execution, payer access, and comparative performance.